Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy
Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects. The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
Topical brinzolamide given bd for 3 months
Iglicki Oftalmologia
Buenos Aires, Argentina
Tel Aviv Medical Center
Tel Aviv, Israel
Change in subretinal fluid (microns)
Change in subretinal fluid as measured by optical coherence tomography
Time frame: 6 months
Change in ETDRS visual acuity (number of letters)
Change in visual acuity from baseline to last follow-up in ETDRS letters
Time frame: 6 months
Change in central macular thickness (microns)
Change in central macular thickness in microns from baseline to last follow-up
Time frame: 6 months
Change in choroidal thickness (microns)
Change in choroidal thickness in microns from baseline to last follow-up
Time frame: 6 months
Time for fluid resolution (days)
Time in days from baseline until fluid resolution, as measured on optical coherence tomography
Time frame: 6 months
Percentage of patients with fluid resolution
Percentage of patients with fluid resolution by last follow-up as seen on optical coherence tomography, out of all study participants
Time frame: 6 months
Quality of life assessment (using NEI-VFQ-25 questionnaires)
Quality of life score as assessed by standard questionnaires
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.